Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bonaventura Clotet

Showing results (1-10 of 730) with videos related to

Pageof 73
Sort By:
Enfermedades Infecciosas Y Microbiologia Clinica|February 7, 2009
[Introduction. Darunavir]Bonaventura Clotet
The Journal of Antimicrobial Chemotherapy|November 17, 2007
Once-daily dosing of nevirapine in HAARTBonaventura Clotet
The New England Journal of Medicine|March 5, 2004
Comparison of regimens as initial therapy for HIVBonaventura Clotet
AIDS Reviews|December 15, 2004
Strategies for overcoming resistance in HIV-1 infected patients receiving HAARTBonaventura Clotet
The Journal of Infectious Diseases|June 16, 2007
CCR5 inhibitors: promising yet challengingBonaventura Clotet
Enfermedades Infecciosas Y Microbiologia Clinica|February 7, 2009
[Position of darunavir in antiretroviral therapy]Bonaventura Clotet
AIDS Reviews|July 24, 2003
HIV protease inhibitors and dyslipidemiaBonaventura Clotet, Eugènia Negredo
Journal of HIV Therapy|February 26, 2005
Therapeutic drug monitoring of antiretroviral agents scenarioJosé Moltó, Bonaventura Clotet
Medicina Clinica|May 9, 2009
[HIV sexual transmission. Should we review the risk among individuals with long-term viral supression?]Joan Romeu, Bonaventura Clotet
The Lancet. Global Health|March 23, 2020
Use of antiviral drugs to reduce COVID-19 transmissionOriol Mitjà, Bonaventura Clotet
Pageof 73

Showing results (1-10 of 730) with videos related to

Sort By:
Pageof 73
Enfermedades Infecciosas Y Microbiologia Clinica|February 7, 2009
[Introduction. Darunavir]Bonaventura Clotet
The Journal of Antimicrobial Chemotherapy|November 17, 2007
Once-daily dosing of nevirapine in HAARTBonaventura Clotet
The New England Journal of Medicine|March 5, 2004
Comparison of regimens as initial therapy for HIVBonaventura Clotet
AIDS Reviews|December 15, 2004
Strategies for overcoming resistance in HIV-1 infected patients receiving HAARTBonaventura Clotet
The Journal of Infectious Diseases|June 16, 2007
CCR5 inhibitors: promising yet challengingBonaventura Clotet
Enfermedades Infecciosas Y Microbiologia Clinica|February 7, 2009
[Position of darunavir in antiretroviral therapy]Bonaventura Clotet
AIDS Reviews|July 24, 2003
HIV protease inhibitors and dyslipidemiaBonaventura Clotet, Eugènia Negredo
Journal of HIV Therapy|February 26, 2005
Therapeutic drug monitoring of antiretroviral agents scenarioJosé Moltó, Bonaventura Clotet
Medicina Clinica|May 9, 2009
[HIV sexual transmission. Should we review the risk among individuals with long-term viral supression?]Joan Romeu, Bonaventura Clotet
The Lancet. Global Health|March 23, 2020
Use of antiviral drugs to reduce COVID-19 transmissionOriol Mitjà, Bonaventura Clotet
Pageof 73